Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients.
Frank M P van HarenLex M van LoonAnne SteinsThomas L SmootCaitlin SasSabrina StaasAlicia B VilasecaRuben A BarberaGustavo VidmarHugo BeccariFrida PopilevskyEleonora DaribayevaBhuvaneshwari VenkatesanSusan MozesRachel PostelNatalie PopilevskiAndrew James WebbQuentin NunesJohn Gerard LaffeyAntonio ArtigasRoger SmithBarry DixonAlice RichardsonHwan-Jin YoonClive PagePublished in: British journal of clinical pharmacology (2022)
Inhaled nebulised UFH in hospitalised patients with COVID-19 was safe. Although statistically significant, inhaled nebulised UFH did not produce a clinically relevant increase in APTT (peak values in the normal range). Urgent randomised evaluation of nebulised UFH in patients with COVID-19 is warranted and several studies are currently underway.